Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: Results by 3-month BCR-ABL1 transcript level Meeting Abstract
| Authors: | Hochhaus, A.; Gambacorti-Passerini, C.; Deininger, M. W.; Mauro, M. J.; Chuah, C.; Kim, D. W.; Dyagil, I.; Glushko, N.; Milojkovic, D.; le Coutre, P. D.; Gutiérrez, V. G.; Reilly, L.; Jeynes-Ellis, A.; Crescenzo, R. J.; Leip, E.; Bardy-Bouxin, N.; Brümmendorf, T. H.; Cortes, J. E. |
| Abstract Title: | Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: Results by 3-month BCR-ABL1 transcript level |
| Meeting Title: | 59th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 130 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2017 Dec 9-12 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2017-12-07 |
| Language: | English |
| ACCESSION: | WOS:000432419404062 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V130.Suppl_1.1618.1618 |
| Notes: | Meeting Abstract: 896 -- Source: Wos |
